ASCO GU 2025

What's the role of Enzalutamide in radioligand therapy?

Milestones of ADT and ARPI treatment in the metastastic prostate cancer

Combining ARPi with PARPi - discussing final OS of TALAPRO-2

Fish-oil supplement for pts on active surveillance

Durvalumab in UTUC

Testosterone Recovery

OS in the TALAPRO-2 trial

Hypo-gonadism bad for survival?

ARPI for which patients?

Darolutamide + ADT reduces risk of progression or death by 46 % in mHSPC

Darolutamide + ADT and Doetaxel improves survivas in mHSPC across age groups

Radiation vs surgery in high risk prostate cancer

Testosterone Recovery after ADT and OS

Who benefits most from ARPIs?

Improved Survival with Enzalutamide + Lutetium

Mevrometostat + Enza: New option for mCRPC

ENZA-p showed OS benefit and improvement in QoL parameters

Final OS analyses

Final OS data for TALA + Enza

MDT in OMPC

Phase 2 Mevrometostat

Radical Prostatectomy VS RT in HRPC

Enza+Lu ile artmis sagkalim

Yuksek risk PCa da RP vs RT

Hangi hastalarda ADT+ARPI

UTUC de Neoadj. Durvalumab+Kemo

Oligometastatik PCa da MDT

Testosteron Geri Gelisi ve Sagkalim

KIM-1 - The most interesting biomarker for RCC?

New data but no new conclusion

Triplet combination in RCC - there's no free lunch with VEGFR

Exciting new substances - but don't over-estimate phase 1 data

Advanced Renal Cell Cancer: Adding more drugs does not translate in greater benefit

KIM-1 in mRCC

Prognostic and predictive biomarkers in mRCC: Looking for the holy grail

KIM-1 in CheckMate 214

AVION trial at mRCC

Casdatifan in refracting RCC

Cáncer de células renales avanzado: añadir más fármacos no se traduce en un mayor beneficio

Biomarcadores prognósticos y predictivos en el CCRm: en busca del Santo Grial

New data, but no new insights for adjuvant treatment of high-risk MIBC patients

Neoadjuvant chemo-immunotherapy in UTUC: new evidence for a challenging indication

Reassuring data on established ADCs and new insights in novel ADCs for urothelial cancer

Exploratory analyses of pCR in NIAGARA: who benefits most from perioperative Durvalumab?

ADC + ICI - The future for MIBC?

New FGFR3 inhibitor

Nivo adjuvant in MIBC - a new standard

The role of ctDNA in bladder cancer

ASCO GU 25 - Summary: Urothelial Cancer

Sacituzumab Tirumotecan shows promising antitumor activity in aUC after platinum-based therapy

New drugs in mUC: The active field of ADCs

Bladder-sparing approaches - are we there yet?

Durvalumab + Platinum-based chemotherapy shows promising efficacy and safety in high-grade UTUC

EV-Pembro continues to be the standard for mTCC

Phase 2 Mevrometastat

Neoadjuvant treatment for UTUC

Adjuvant Nivo - independent from previous therapy

HER2 - new marker for bladder preservation

A possible new standard for mUC

Promising combination for perioperative setting

Preliminary results of neoadjuvant chemoimmunotherapy in UTUC

Promising combination for perioperative setting

Nuevos fármacos en mUC: El campo activo de las ADCs

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

RPLND in metastatic Seminoma

Testicular cancer: Reinventing the wheel

Metastatik seminomda Primer RPLND

Cáncer de testículo: reinventar la rueda